NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002
Executive Summary
FDA has received only 16 NDA submissions for new molecular entities thus far in fiscal 2002
You may also be interested in...
FDA Wants To Help You Develop Drugs
The agency’s report on innovative drug approvals in FY 2012 documents the successful performance metrics for the 35 novel medicines, including first-cycle review rates and on-time user fee targets, but it notes that a larger problem lies in early stages of drug discovery and development – and it thinks it can help.
Drug Approvals Will Be Down “Significantly” In ’05, FDA’s Gottlieb Predicts
The number of new molecular entities approved by FDA in 2005 will be significantly fewer than in recent years, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb predicted
Drug Approvals Will Be Down “Significantly” In ’05, FDA’s Gottlieb Predicts
The number of new molecular entities approved by FDA in 2005 will be significantly fewer than in recent years, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb predicted